Navigation Links
Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
Date:6/15/2010

re being used primarily in connection with perifosine, Aeterna Zentaris' lead oncology compound that is being developed in collaboration with its North American partner, Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), following various positive developments announced with respect to perifosine during the first quarter of 2010.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by the Company with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting Aeterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
2. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
3. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
4. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
5. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
6. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
7. AEterna Zentaris Announces Appointment of New Board Member
8. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
9. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
10. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
11. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... State University have developed a cheap and easy ... density. The researchers hope the findings will foster ... using nanowires, from nanoelectronics to nanosensors, especially on ... "Alignment is a critical first step for ...
... CAMBRIDGE, Mass., Feb. 28, 2011 Idenix Pharmaceuticals, Inc. ... in the discovery and development of drugs for the ... results for the fourth quarter and year ended December ... cash equivalents totaled $46.1 million. ...
... Feb. 28, 2011 Verenium Corporation (Nasdaq: ... specialty enzymes, today announced that Terminal 6, a major ... begun use of Verenium,s Purifine enzymatic degumming process at ... enzymatic degumming is a novel process that significantly increases ...
Cached Biology Technology:Stretched rubber offers simpler method for assembling nanowires 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2010 Financial Results 7World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 2World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 3World's Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Verenium's Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval 4
(Date:12/17/2014)... N.C. , Dec. 16, 2014 Valencell, ... licensed its PerformTek biometric technology to industry leaders such ... highly accurate, clinically validated, biometric wearable products. These products ... 6-9 in Las Vegas . ... technology is accurate, flexible and robust – with the ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... You,ve been here before: you desperately need to ... password, site key or the answer to your secret question. ... Today, Hoyos Labs , a digital ... finally put an end to the frustration that comes with ... 1U leverages a user,s smartphone to acquire his or her ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... BOSTON (3:00 p.m. ET, November 1, 2010) A ... may provide a new approach to cancer treatment, according ... Proceedings of the National Academy of Sciences ... inhibitors), limited tumor growth in mice by inducing cell ...
... The rate at which lead poisoning has struck young Rhode ... a Brown University-led geographic analysis of comprehensive health department data ... cases of lead poisoning, researchers have been able to help ... that 12-year period, some census blocks in the state had ...
... as a large-scale, emission-free energy source, bat and bird ... annually. Migratory bats, such as the hoary bat, are ... they fly their routes in the forested ridges of ... immediate area, but is also detrimental to ecosystem health ...
Cached Biology News:Of 50,000 small molecules tested to fight cancer, 2 show promise 2Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2Slight change in wind turbine speed significantly reduces bat mortality 2
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
...
... Mynox is the first ... by killing them, and not ... is the only anti-mycoplasma agent ... clean virus stocks directly. The ...
Biology Products: